Immune Design company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired

Total Raised






About Immune Design

Immune Design is a clinical-stage biotechnology company developing two synergistic platforms of vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs technologies that target dendritic cells for more precise activation of the immune response. These include DCVex, a lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAAS, a TLR4 agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response.On April 2nd, 2019, Immune Design was acquired by Merck at a valuation of $300M.

Immune Design Headquarter Location

1616 Eastlake Ave E Suite 310

Seattle, Washington, 98102,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Immune Design

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immune Design is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Immune Design Patents

Immune Design has filed 29 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Molecular biology
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Virology, Virus families, Biotechnology, Genetics


Application Date


Grant Date



Related Topics

Molecular biology, Virology, Virus families, Biotechnology, Genetics



Latest Immune Design News

Synovial Sarcoma Treatment Market Size, Growth, Trends | Industry Report, 2019 – 2025| Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc, Immune Design Corp

Jan 30, 2020

| Industry Report, 2019 – 2025| Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc, Immune Design Corp Los Angeles, United State, July 15, 2019, - The latest report published by QY Research presents a thorough analysis of the global Synovial Sarcoma Treatment market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it to the current market trends, to chart the trajectory. For a detailed discussion about the global Synovial Sarcoma Treatment market, analysts have segmented the market on the basis of application, product, and end users. The research report has been collated using primary and secondary research methodologies to provide the readers with an accurate and precise understanding of the Synovial Sarcoma Treatment market ongoing developments. Analysts have used Porter’s five forces analysis, SWOT analysis, and PESTLE analysis to determine the course key vendors are likely to take in the coming years. The research report also includes an assessment of the financial outlook of these vendors, Synovial Sarcoma Treatment market growth strategies, and their expansion plans for the forecast period. All of the information present in the research report about the global Synovial Sarcoma Treatment market has been authenticated by market experts. Get PDF template of this report: Competitive Landscape In the last chapter, the analysts have studied the competitive landscape present in the global Synovial Sarcoma Treatment market. The chapter also includes comments and recommendations by market experts to help the readers make the right decisions for their businesses for the forecast period. The chapter on competitive landscape presents a list of achievements made by these companies so far, mergers and acquisitions, and product innovations. Synovial Sarcoma Treatment Market Leading Players Adaptimmune Therapeutics Plc Market Segmentation The extensive report on the global Synovial Sarcoma Treatment market includes an executive summary that gives a brief description of the overall market, its drivers, restraints, leading segments, and competitive landscape. Each part of the executive is separately explained in the research report through dedicated chapters. The chapters are complete with precise calculations through charts and graphs. The publication also includes individual chapters on various segments present in the market and the relevant sub-segments. Analysts have provided historical revenues and estimated revenues for all of the segments. Sales of products and the evolution of end users have also been studied in the research report. The chapter on geographical analysis assesses the regional markets. It takes a granular view of the changing socio-political conditions, weather changes, and annual budgets of nations to determine their impact on the overall market. Synovial Sarcoma Treatment Segmentation by Product ACXT-3102 Hospital Others Report Objectives • Analyzing the size of the global Synovial Sarcoma Treatment market on the basis of value and volume. • Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Synovial Sarcoma Treatment market. • Exploring the key dynamics of the global Synovial Sarcoma Treatment market. • Highlighting important trends of the global Synovial Sarcoma Treatment market in terms of production, revenue, and sales. • Deeply profiling top players of the global Synovial Sarcoma Treatment market and showing how they compete in the industry. • Studying manufacturing processes and costs, product pricing, and various trends related to them. • Showing the performance of different regions and countries in the global Synovial Sarcoma Treatment market. • Forecasting the market size and share of all segments, regions, and the global market. About Us: QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry. Post Views: 114

  • When was Immune Design founded?

    Immune Design was founded in 2008.

  • Where is Immune Design's headquarters?

    Immune Design's headquarters is located at 1616 Eastlake Ave E, Seattle.

  • What is Immune Design's latest funding round?

    Immune Design's latest funding round is Acq - P2P.

  • How much did Immune Design raise?

    Immune Design raised a total of $84.53M.

  • Who are the investors of Immune Design?

    Investors of Immune Design include Merck & Co., Alta Partners, Versant Ventures, The Column Group, ProQuest Investments and 5 more.

  • Who are Immune Design's competitors?

    Competitors of Immune Design include ISA Pharmaceuticals, FluGen, CoImmune, Scancell, United Biomedical, Bellicum Pharmaceuticals, Vaxart, VaxInnate Corporation, Activate Immunotherapy, Immune Targeting Systems and 14 more.

You May Also Like

ISA Pharmaceuticals

ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.

Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology.  The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University.  Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See


ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.

Lofarma S.p.A.

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.


Vaxent has developed a StepNovA vaccine for Group A streptococcus


Creatogen, a spin-off from the Max Planck Institute for Infection Biology in Berlin, develops bacterial carriers for oral delivery to treat and prevent acute and chronic diseases caused by an imbalance of the immune system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.